NLS Pharmaceutics AG: NLS Pharmaceutics Announces Launch of Paid for Named Patient Program with Mazindol ER for Idiopathic Hypersomnia, a Serious Sleep Disorder with No Approved Treatment Options in Europe

ZURICH, SWITZERLAND / ACCESSWIRE / November 23, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP), (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery

Related Keywords

Switzerland ,Zurich ,Züsz ,United Kingdom ,Swiss ,Alex Zwyer ,Cindy Rizzo ,Drug Administration ,Nasdaq ,Pharmaceutics Ltd ,Exchange Commission ,European Union ,Caligor Coghlan Pharma Services ,European Medicines Agency ,Patient Program ,Named Patient Program ,Chief Executive Officer ,Orphan Drug Designation ,Mazindol Controlled Release ,Pharmaceutics ,Nnounces ,Launch ,Aid ,Amed ,Patient ,Program ,Mazindol ,Idiopathic ,Hypersomnia ,Serious ,Sleep ,Disorder ,Approved ,Treatment ,Options ,Europe ,